

REMARKS

Claims 2, 3 and 5 have been amended to indicate that the binding of the monospecific antisera or immunoglobulin composition occurs via the variable region. Support for the amendment can be found in Figures 7 and 8.

Claims 4, 5, 7, 8, and 27-30 have been amended by inserting the term “adhesin” between “BabA” and “protein.”

No new matter has been added.

Rejections Under 35 U.S.C. § 102(b)

Durrant et al.

The Examiner has maintained her rejections of claims 3-8, 16, 19 and 27-30 as anticipated by Durrant et al (1993). The Examiner states that Durrant et al disclose a rat polyclonal antiserum that comprises purified immunoglobulin anti-idiotypic antibodies that evidence the Lewis-B antigen epitope confirmation, which would specifically bind to and form a complex with *Helicobacter pylori* Lewis-B antigen binding antigen.

Applicants respectfully traverse.

Applicants have amended the claims to require that isolated monospecific antisera and monospecific immunoglobulin composition of the invention recognizes a BabA antigen and comprise a variable region of a BabA immunoglobulin that binds the BabA antigen and exhibits specific activity to a BabA adhesin protein. The anti-idiotypic antibody of Durrant does not do this. Thus, Applicants respectfully request reconsideration and removal of the rejection.

Uemura et al

The Examiner has maintained her rejection of claims 3-8, 16, 19 and 27-30 as anticipated by Uemura et al in light of Boren. The Examiner contends that the monospecific immunoglobulin compositions of Uemura et al. that comprise secretory sIgA from human colostrum specifically bind BabA because the claims do not specifically recite that the claimed antibodies bind to BabA via the antibody's hypervariable region. Applicants respectfully traverse.

Applicants have amended the claims to require that isolated monospecific antisera and monospecific immunoglobulin composition of the invention recognizes a BabA antigen and comprise a variable region of a BabA immunoglobulin that binds the BabA antigen and exhibits specific activity to a BabA adhesin protein. The interaction of secretory sIgA from human colostrum does not occur through the hypervariable region. Thus, Applicants respectfully request reconsideration and removal of the rejection.

Rejections Under 35 U.S.C. § 103

The Examiner has maintained her rejection of claim 2 as obvious over Boren et al. The Examiner contends that Boren teaches detection of a *Helicobacter pylori* blood group binding protein antigen using binding of colostrum IgA. Applicants respectfully traverse.

Applicants have amended the claims to require that the isolated monospecific antisera and monospecific immunoglobulin composition of the invention recognizes a BabA antigen and comprise a variable region of a BabA immunoglobulin that binds the BabA antigen and exhibits specific activity to a BabA adhesin protein. The interaction of

secretory sIgA from human colostrum does not occur through the hypervariable region.

Thus, Applicants respectfully request reconsideration and removal of the rejection.


Accordingly, in view of the above amendments and remarks, reconsideration of the rejections and allowance of the claims of the present application are respectfully requested. In the event that the Amendment does not place the present application into condition for allowance, entry thereof is respectfully requested as placing the present application into better condition for appeal.

Should there be any additional matters remaining in this application, the Examiner is strongly encouraged to contact Susan W. Gorman (Reg. No: 47,604) at 858-792-8855 in order to discuss these matters.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Dated: January 22, 2007

Respectfully submitted,

By  # 47,604
Leonard R. Svensson
Registration No.: 30,330
BIRCH, STEWART, KOLASCH & BIRCH, LLP
12770 High Bluff Drive
Suite 260
San Diego, California 92130
(858) 792-8855
Attorney for Applicant